Biocon Limited , a leading global biopharmaceuticals company, has announced robust financial results for the first quarter of fiscal year 2026, demonstrating significant growth across its key business segments.

Financial Highlights

Biocon's consolidated revenue from operations for Q1 FY26 reached Rs 3,942.00 crore, marking a 15% year-on-year increase. The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) grew by 19% to Rs 829.00 crore, with an EBITDA margin of 21%. Core EBITDA, which excludes R&D expenses, licensing, forex, and other items, stood at Rs 1,003.00 crore, up 11% from the previous year, with a margin of 25%.

Profit Before Tax (PBT) before exceptional items saw a substantial rise of 72% to Rs 97.00 crore, while Net Profit before exceptional items increased by 342% to Rs 31.00 crore.

Segment Performance

Biosimilars

The Biosimilars segment, operated by Biocon Biologics, emerged as the star performer with an 18% year-on-year revenue growth, reaching Rs 2,458.00 crore. This segment's EBITDA rose by 36% to Rs 645.00 crore, with a margin improvement of 300 basis points sequentially.

Contract Research, Development & Manufacturing Organization (CRDMO)

The CRDMO segment, represented by Syngene, reported an 11% year-on-year growth with revenues of Rs 875.00 crore. EBITDA for this segment increased by 19% to Rs 224.00 crore.

Generics

The Generics business showed steady growth with a 6% year-on-year increase in revenue, reaching Rs 697.00 crore. This growth was primarily driven by recent drug product launches and higher API volumes.

Key Developments

Biocon achieved several milestones during the quarter:

• Received U.S. FDA approval for Kirsty™ (bAspart), an interchangeable biosimilar insulin aspart.
• Launched Yesafili™, a biosimilar aflibercept, in Canada, marking the company's entry into ophthalmology and its 10th biosimilar globally.
• Obtained regulatory approvals for biosimilar denosumab products in Europe and the UK.
• Successfully raised Rs 4,500.00 crore through a Qualified Institutions Placement (QIP), strengthening the company's balance sheet.

Management Commentary

Kiran Mazumdar-Shaw, Chairperson of Biocon Group, stated, "Biocon opened FY26 with a strong performance, driven by continued gains in Biosimilars and CRDMO, and a steady showing in Generics. The recent QIP has strengthened our balance sheet and enables us to increase our ownership in Biocon Biologics by facilitating the exit of structured equity investors, aligning capital structure with long-term strategic priorities."

Shreehas Tambe, CEO & Managing Director of Biocon Biologics Limited, commented on the Biosimilars segment's performance, saying, "As we enter the 'Accelerate' phase, we are confident in our ability to scale, deepen market presence, and deliver sustained growth."

Outlook

With a strong start to FY26, Biocon appears well-positioned for continued growth. The company's focus on expanding its biosimilars portfolio, enhancing manufacturing capabilities, and strategic investments in scientific capabilities are expected to drive long-term value creation.

Biocon's performance in Q1 FY26 reflects its robust business model and successful execution of growth strategies across its diverse portfolio of biopharmaceutical products and services.

Biocon Ltd. , a prominent player in the Indian biopharmaceutical sector, witnessed a significant block trade on the National Stock Exchange (NSE) today. The transaction involved approximately 1,623,691 shares of the company, highlighting substantial investor interest in the stock.

Block Trade Details

The block deal was executed at a price of Rs. 374.90 per share, resulting in a total transaction value of Rs. 60.87 crores. This large-scale trade underscores the liquidity and market depth for Biocon's shares on the NSE.

Market Impact

Block trades of this magnitude often attract attention from market participants as they can potentially influence short-term price movements and indicate shifts in institutional holdings. However, it's important to note that the immediate impact on Biocon's stock price may vary depending on market conditions and investor sentiment.

About Biocon Ltd.

Biocon Ltd. is a leading biopharmaceutical company headquartered in Bangalore, India. The company is known for its innovative work in developing affordable biosimilars, novel biologics, and complex small molecule APIs. Biocon has a strong presence in various therapeutic areas, including diabetes, oncology, and immunology.

While this block trade represents a significant transaction, investors and analysts will likely be watching for any potential disclosures or announcements from the company that might provide context to this large-scale share movement.